Sanofi Consumer Sales Slow As Pandemic-Driven Surge Ends, But OTC Xyzal Line Still Shines
Sanofi says slower sales after consumers stockpiled cold and cough products in Q1 combined with OTC Zantac removal US and Canada drove 8% drop in consumer health care sales in Q2 to $1.18bn. Xyzal allergy brand had stellar results in the US and worldwide sales grew 76.9%.
You may also be interested in...
Major Europe-based consumer health players GSK, Sanofi, Bayer and Reckitt are all hoping for a sales boost in Q2 following a difficult Q1 due to the almost non-existent cough and cold season. This earnings preview highlights what to look out for as these four firms report their second-quarter results over the coming weeks.
C&D said sales of its brands including vitafusion, L’il Critters and PB8 supplements, Arm & Hammer, Aim and Close-Up toothpastes and Waterpick and Spinbrush power toothbrushes helped drive 8.8% growth to $386.4m for the personal and health care categories.
President of Estée Lauder's Origins business Julie Van Ongevalle will take the reins of Sanofi's global Consumer Healthcare business from September. The French firm is banking on Van Ongevalle's digital and brand-building experience to take the business to the next level.